Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeDropped

Termination of the Agreement With Viatris for a Hyperlipidemia Treatment

First written in FY2026. 1 of 1 entries say "Dropped", first in FY2026. Latest entry: FY2026.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Termination of the development, manufacturing and marketing rights license agreement with Viatris for a hyperlipidemia treatment drugA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026DroppedAnnual report

    「2025年12月までに、ヴィアトリス社との高脂血症治療剤の開発・製造・販売権許諾に関する契約は終了しました。」

    ヴィアトリス社との高脂血症治療剤の開発・製造・販売権許諾契約が2025年12月までに終了したことを記載している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Termination of the Agreement With Viatris for a Hyperlipidemia Treatment | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) | Komori